Psoriasis, metabolic syndrome and COVID-19: a case report

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The COVID-19 pandemic that broke out in 2020 is still having a huge impact on dermatological practice. Patients suffering from moderate and severe forms of psoriasis, among which the majority require long-term immunosuppressive therapy, cause significant concern among dermatologists. It is now known that psoriasis may be a predisposing factor in the severe course of COVID-19, as systemic inflammation in psoriasis and comorbid conditions can cause the development of a cytokine storm and an increased risk factor for an unfavorable outcome. To date, the accumulated knowledge to determine the extent of the impact of COVID-19 on infected psoriasis patients receiving systemic treatment is insufficient. Practicing dermatologists are faced with the question of the possibility and safety of continuing systemic biological therapy in patients with psoriasis with comorbid pathology and COVID-19. The article presents the observation of a patient with severe plaque psoriasis, metabolic syndrome and COVID-19 who received systemic biological therapy. Keywords: psoriasis, COVID-19, cardiovascular complications, targeted therapy for psoriasis

Толық мәтін

Рұқсат жабық

Авторлар туралы

Irina Vladimirova

Dermatological and Venereological Dispensary №10 - Clinic of Dermatology and Venereology; St. Petersburg State University

Email: ivladimirva@rambler.ru
Cand. Sci. (Med.), Dermatovenereologist St. Petersburg, Russia

Әдебиет тізімі

  1. Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205-12. doi: 10.1111/jdv.13854.
  2. Elmas O.F, Demirbas A., Kutlu O., et al. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther. 2020;33:e13858. doi: 10.1111/dth.13858.
  3. Бакулев А.Л. Эволюция представлений о псориазе и терапевтических подходах по ведению пациентов. BCD-085 - первый отечественный генно-инженерный биологический препарат для лечения больных псориазом. Вестник дерматологии и венерологии. 2018;94(5):26032
  4. Свечникова Е.В., Маршани З.Б., Фомин К.А., Евдокимов Е.Ю. Новая коронавирусная инфекция в аспекте псориаза. Клиническая дерматология и венерология. 2021;20(3):77-84
  5. Kearns D.G., Uppal S., Chat V.S., Wu J.J. Use of systemic therapies for psoriasis in the COVID-19 era [published online ahead of print, May 27, 2020. J Dermatol Treat. 2020;33(1):1-14. doi: 10.1080/09546634.2020.1775774.
  6. Gisondi P., Piaserico S., Conti A., Naldi L. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020;34(6):1196-201. doi: 10.1111/jdv.16515.
  7. Адаскевич В.П. Кожные проявления у пациентов с коронавирусной инфекцией COVID-19 и особенности работы дерматовенеролога в период пандемии. Consilium Medicum. 2020;22(7):9-13.
  8. Hawkes J.E., Yan B.Y., Chan T.C., Krueger J.G. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J. Immunol. 2018;201(6):1605-13. Doi: 10.40 49/ jimmunol.1800013.
  9. Cohen J.M., Perez-Chada L.M., De Kouchkovsky D, Gehlhausen J.R. Psoriasis and COVID-19: a multifactorial consideration. J Dermatol Treatment. 2022;33(2):1174. doi: 10.1080/09546634.2020.1782818.
  10. Davidovici B.B., Sattar N., Prinz J.C., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. Doi: 10.1038/ jid.2010.103.
  11. Смирнова И.О, Владимирова И.С. Псориаз и сердечно-сосудистая коморбидность (обзор литературы). Медицинский алфавит. 2020;6:18-21.
  12. Chiricozzi A., Gisondi P., Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863-72. doi: 10.1080/14656566.2019.1583207.
  13. Dugail I., Amri E.Z., Vitale N. High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification [published online ahead of print, July 08, 2020. Biochim. 2020;S0300-9084(20)30155-3. doi: 10.1016/j.biochi.2020.07.001.
  14. Бакулев А.Л., Кравченя С.С. Применение гепатопротекторов при псориазе: сравнительная клинико-лабораторная и ультрасонографи-ческая оценка эффективности. Вестник дерматологии. 2010;1:112-17.
  15. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diab. 2012;2:e54. doi: 10.1038/nutd.2012.26.
  16. Price K.N., Frew J.W., Hsiao J.L., Shi V.Y. COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology. J Am Acad Dermatol. 2020;82(5):e173-75. Doi: 10.1016/j. jaad.2020.03.046.
  17. Кубанов А.А., Бакулев А.Л., Кохан М.М. и др. Рекомендации Российского общества дерматовенерологов и косметологов по системной терапии псориаза в период пандемии COVID-19. Вестник дерматологии и венерологии. 2020;97(2):9-13.
  18. Потекаев Н.Н., Жукова О.В., Артемьева С.И., Острецова М.Н. Опыт ведения пациентов с псориазом, получающих таргетную терапию в период пандемии COVID-19. Медицинский совет. 2020;(12):10-6
  19. Zou Yu., Meng Z. Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19. J Inflammat Res. 2021;14:5611-18. doi: 10.2147/JIR. S329252.
  20. Amerio P., Prignano F., Giuliani F., Gualdi G. COVID-19 and psoriasis: should we fear for patients treated with biologics? Dermatol Ther. 2020;33(4):e13434. doi: 10.1111/dth.13434.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>